Cargando…
Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have been shown to have unprecedented efficacy in B cell malignancies, most notably in B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate using anti-CD19 CAR-T cells. However, CAR T-cell therapy for so...
Autores principales: | Xia, An-Liang, Wang, Xiao-Chen, Lu, Yi-Jun, Lu, Xiao-Jie, Sun, Beicheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685771/ https://www.ncbi.nlm.nih.gov/pubmed/29163850 http://dx.doi.org/10.18632/oncotarget.19361 |
Ejemplares similares
-
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
por: Yan, Lingli, et al.
Publicado: (2018) -
CAR-T Therapies in Solid Tumors: Opportunities and Challenges
por: Guzman, Grace, et al.
Publicado: (2023) -
Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities
por: Chen, Long, et al.
Publicado: (2022) -
A Systematic Review of the Role of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in the Treatment of Solid Tumors
por: Siddiqui, Raheel S, et al.
Publicado: (2021) -
Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
por: Mirzaei, Hamid R., et al.
Publicado: (2017)